Atara Biotherapeutics, Inc. (ATRA): Price and Financial Metrics

Atara Biotherapeutics, Inc. (ATRA): $1.54

0.04 (+2.67%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add ATRA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#226 of 380

in industry

ATRA Price/Volume Stats

Current price $1.54 52-week high $9.34
Prev. close $1.50 52-week low $1.45
Day low $1.46 Volume 2,211,900
Day high $1.57 Avg. volume 1,349,397
50-day MA $2.52 Dividend yield N/A
200-day MA $3.71 Market Cap 150.88M

ATRA Stock Price Chart Interactive Chart >

ATRA POWR Grades

  • Value is the dimension where ATRA ranks best; there it ranks ahead of 63.03% of US stocks.
  • The strongest trend for ATRA is in Sentiment, which has been heading down over the past 179 days.
  • ATRA's current lowest rank is in the Sentiment metric (where it is better than 1.05% of US stocks).

ATRA Stock Summary

  • Of note is the ratio of ATARA BIOTHERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.17% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 392.92%, ATARA BIOTHERAPEUTICS INC's debt growth rate surpasses 96.12% of about US stocks.
  • Revenue growth over the past 12 months for ATARA BIOTHERAPEUTICS INC comes in at 138.51%, a number that bests 95.43% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ATARA BIOTHERAPEUTICS INC, a group of peers worth examining would be RNA, INVZ, FATE, ARVN, and AFMD.
  • ATRA's SEC filings can be seen here. And to visit ATARA BIOTHERAPEUTICS INC's official web site, go to www.atarabio.com.

ATRA Valuation Summary

  • ATRA's EV/EBIT ratio is -1.1; this is 109.17% lower than that of the median Healthcare stock.
  • ATRA's price/sales ratio has moved NA NA over the prior 105 months.

Below are key valuation metrics over time for ATRA.

Stock Date P/S P/B P/E EV/EBIT
ATRA 2023-05-23 3.5 3.1 -0.9 -1.1
ATRA 2023-05-22 3.6 3.2 -1.0 -1.1
ATRA 2023-05-19 3.6 3.2 -1.0 -1.1
ATRA 2023-05-18 3.5 3.1 -0.9 -1.1
ATRA 2023-05-17 3.5 3.1 -0.9 -1.1
ATRA 2023-05-16 3.5 3.1 -0.9 -1.1

ATRA Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 12.41%.
  • Its 3 year net income to common stockholders growth rate is now at -36.94%.
  • Its year over year net income to common stockholders growth rate is now at -12.35%.
Over the past 70 months, ATRA's revenue has gone up $63,573,000.

The table below shows ATRA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 63.573 -270.43 -228.302
2022-09-30 70.9 -247.819 -247.079
2022-06-30 71.811 -241.74 -247.652
2022-03-31 24.102 -239.353 -349.911
2021-12-31 20.34 -220.522 -340.141
2021-09-30 12.792 -190.373 -328.099

ATRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRA has a Quality Grade of C, ranking ahead of 37.13% of graded US stocks.
  • ATRA's asset turnover comes in at 0.025 -- ranking 360th of 682 Pharmaceutical Products stocks.
  • HGEN, ARMP, and ZSAN are the stocks whose asset turnover ratios are most correlated with ATRA.

The table below shows ATRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.025 1 -1.135
2021-06-30 0.015 1 -1.059
2021-03-31 0.007 1 -0.973
2020-12-31 0.000 NA -1.036
2020-09-30 0.000 NA -1.093
2020-06-30 0.000 NA -1.152

ATRA Price Target

For more insight on analysts targets of ATRA, see our ATRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.38 Average Broker Recommendation 1.41 (Moderate Buy)

Atara Biotherapeutics, Inc. (ATRA) Company Bio


Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. The company was founded in 2012 and is based in South San Francisco, California.


ATRA Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRA Latest Social Stream


Loading social stream, please wait...

View Full ATRA Social Stream

Latest ATRA News From Around the Web

Below are the latest news stories about ATARA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ATRA as an investment opportunity.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be

Today is shaping up negative for Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders, with the analysts delivering...

Yahoo | May 18, 2023

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 8, 2023

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

THOUSAND OAKS, Calif., May 08, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts.

Yahoo | May 8, 2023

The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong...

Yahoo | May 7, 2023

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif., May 05, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 6,250 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biot

Yahoo | May 5, 2023

Read More 'ATRA' Stories Here

ATRA Price Returns

1-mo -47.08%
3-mo -55.10%
6-mo -65.63%
1-year -70.04%
3-year -84.07%
5-year -96.86%
YTD -53.05%
2022 -79.19%
2021 -19.71%
2020 19.19%
2019 -52.59%
2018 91.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!